EIF2AK2 Knockout DLD-1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EIF2AK2 gene in a DLD-1 human colorectal adenocarcinoma background. This loss-of-function model is designed to abolish PKR kinase expression across a mixed cell pool, enabling bulk analysis of PKR-dependent signaling without clonal selection. By disrupting EIF2AK2 via non-homologous end joining, this population facilitates the study of downstream molecular events that are directly regulated by PKR activity in epithelial-derived cancer cells. The product is supplied as a viable, polyclonal population ready for immediate expansion and downstream applications, including functional genomics, drug screening, and pathway characterization.
DLD-1 cells are a widely characterized adherent epithelial cell line isolated from a colorectal adenocarcinoma, a model that retains key oncogenic mutations and phenotypic features of colorectal tumors. This cell line is commonly employed to investigate colorectal cancer biology, including signal transduction mechanisms, tumor suppressor pathways, and responses to chemotherapeutic agents. Its well-documented growth characteristics and extensive use in cancer research make it a robust platform for genetic perturbation. Within this context, knocking out EIF2AK2 allows researchers to dissect the contribution of PKR-mediated stress responses to colorectal cancer cell proliferation, survival, and drug sensitivity, particularly under conditions that activate the integrated stress response.
The EIF2AK2 gene encodes protein kinase R (PKR), a serine/threonine kinase that serves as a central mediator of cellular stress and innate antiviral immunity. PKR is activated by double-stranded RNA (dsRNA) or by protein activators such as PACT/PRKRA, and in turn interacts with factors like TRBP, the IKK complex, and Hsp90. Upon activation, PKR phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2??) at Ser51, which inhibits the guanine nucleotide exchange factor eIF2B, thereby reducing ternary complex formation and leading to global translational attenuation. This blockade paradoxically enhances the translation of selective mRNAs, including the transcription factor ATF4, which induces expression of CHOP and GADD34 to drive either adaptive recovery or apoptosis. Upstream regulators of PKR include type I interferon, TNF-??, ER stress, and nutrient deprivation, placing PKR at the nexus of eIF2 signaling, the integrated stress response, NF-??B activation, and MAPK cascades.
In the DLD-1 colorectal cancer background, loss of PKR is particularly valuable for examining how tumor cells modulate translational control and stress-induced apoptosis. PKR has been implicated in tumor suppression and in the regulation of cell growth, while its dysregulation may contribute to colorectal cancer progression and therapeutic resistance. By ablating EIF2AK2, this polyclonal knockout model permits the investigation of PKR??s role in mediating responses to dsRNA mimics, viral challenges, or chemotherapeutic stressors that converge on the integrated stress response. It also enables dissection of PKR crosstalk with oncogenic signaling pathways frequently altered in colorectal cancer, providing a physiologically relevant system for functional validation.
This EIF2AK2 knockout cell population is suitable for a diverse range of experimental approaches. Researchers can employ western blotting to assess phospho-eIF2?? (Ser51) and total eIF2?? levels following treatment with dsRNA or ER stress inducers, or use RT-qPCR to quantify downstream effectors like ATF4 and CHOP. Immunofluorescence can visualize PKR localization changes in the parental line, and polysome profiling can reveal translational shifts. Functional studies include viral infection assays to test innate immune competence, caspase activity assays to measure apoptosis induction, and drug sensitivity testing to evaluate chemotherapeutic responses. Transcriptomic analysis via RNA-seq can further define PKR-dependent stress gene signatures. For further technical details or to inquire about this product, please contact Ascent Research.
